Paul GibbonsMcDermott + Bull has successfully placed Lisa Downey as Chief Executive Officer at DrugBank. In this role, Lisa will lead the company’s next phase of growth, deepening its impact across pharmaceutical R&D and AI-driven drug discovery while scaling commercial operations, strategic partnerships, and product innovation.
Lisa brings more than 18 years of leadership experience across life sciences, real-world data, and health technology. She most recently served as Vice President, Commercial Strategy & Data Products at Clarivate, where she built and scaled a rare disease and genomics data business from concept through commercialization, securing enterprise clients and high-value partnerships. Her earlier roles at Clarivate include leading global go-to-market strategy, operational excellence initiatives, and M&A integration efforts. Lisa also brings private equity experience from DW Healthcare Partners, where she led deal origination across healthcare services and technology. She holds a BSc in Chemistry from Western University and completed the Yale Executive Leadership Program.
DrugBank is a leading biomedical data company delivering structured, high-fidelity drug information to accelerate discovery, development, and decision-making across the global life sciences ecosystem.
This executive search was completed by McDermott + Bull Managing Partner Paul Gibbons, Partner Ken Dropiewski, Principal Brittany Stansfield, and Senior Consultant Jennifer Ness.